Prescription medicine
Cangrelor Brand names: Kengreal
Cangrelor (Kengreal) is a prescription medicine with an FDA approval on record since 2015. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
Check it at the source: the cangrelor FDA label on DailyMed (effective October 21, 2025, Chiesi USA, Inc.); the NDA 204958 record on Drugs@FDA; every cangrelor label on DailyMed.
Highlights of the record
FDA label of October 21, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageKENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )].
Forms and strengths
- 50 mg
Injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- June 22, 2015 Kengreal, Chiesi; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first August 11, 2025; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 1 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- July 10, 2035 Kengreal injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 399 through July 30, 2026
What is cangrelor used for?
From the label: indications and usageKENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. […]
Conditions named in the indications of cangrelor's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: P2Y12 Platelet Inhibitor.
Source: FDA drug label (KENGREAL), Chiesi USA, Inc., effective October 21, 2025 (SPL set 88b434fa-8891-4fd5-9d86-7ea64667c08f), via openFDA; the full label on DailyMed
Is there a generic for cangrelor (Kengreal)?
The FDA approved the first generic cangrelor on August 11, 2025. 2 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists cangrelor from 1 labeler under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 7 patents for Kengreal injection, the last expiring on July 10, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2025 first generic approved
- 2035 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the cangrelor label say about other medicines?
The cangrelor label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clopidogrel | drug interactions | DRUG INTERACTIONS Clopidogrel: Do not administer during KENGREAL infusion. |
| Prasugrel | drug interactions | Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered. |
Source: FDA drug label (KENGREAL), Chiesi USA, Inc., effective October 21, 2025 (SPL set 88b434fa-8891-4fd5-9d86-7ea64667c08f), via openFDA; the full label on DailyMed
What do FAERS reports show for cangrelor?
The FDA Adverse Event Reporting System holds 399 reports that list cangrelor among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 84 are coded as a death and 81 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as cangrelor?
2 other medicines are given the same way (intravenous) and in the same FDA class as cangrelor or labeled mainly for the same use (heart attack and coronary artery disease), the same class first. Heart attack and coronary artery disease lists all 38 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Eptifibatide | Heart attack and coronary artery disease | 8 labelers | n/a | No current entry |
| Tirofiban | Heart attack and coronary artery disease | 4 labelers | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other p2y12 inhibitors
- the pharmacologic class, with prices and generics
- Cangrelor side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other